Solveig Elisabeth Hellebust

DNB ASA provides banking and financial services. It operates through the following segments: Personal Customers; Small & Medium-Sized Enterprises; Large Corporates & International Customers; Trading; and Traditional Pension Products. The Personal Customers segment includes the group's total products and activities to private customers in all channels, both digital and physical. The segment offers products through Norway's various distribution networks which include branches, telephone banking, digital banking, real estate broking as well as external channels. The Small & Medium-Sized Enterprises segment is responsible for product sales and advisory services to small and medium-sized enterprises in Norway. The Large Corporates & International Customers segment includes Norwegian and international corporate customers and all customers served by DNB's subsidiary banks in the Baltics and Poland. The Trading segment includes market making and other trading activities in fixed income, currencies and commodities as well as equities, including risk management of the risk inherent in customer transactions. The Traditional Pension Products segment includes traditional defined-benefit pension products in DNB Livsforsikring. The company was founded in 1822 and is headquartered in Oslo, Norway.

Norges Bank operates as the Central Bank of Norway. The bank provides research for monetary policy, financial stability, and investment management. It focuses on credit markets, the behavior of financial institutions, portfolio management, and the functioning of equity markets. Norges Bank was founded on June 14, 1816 and is headquartered in Oslo, Norway.

Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway.

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway.

Part of Linde Plc, Yara Pensjonskasse is a Norwegian company that provides insurance brokerage services. The private company is based in Oslo, Norway.